Vascular Biogenics (STU:0VB) Cyclically Adjusted PB Ratio: (As of Jul. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Vascular Biogenics Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vascular Biogenics  (STU:0VB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Vascular Biogenics Cyclically Adjusted PB Ratio Related Terms


Vascular Biogenics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Vascular Biogenics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vascular Biogenics Cyclically Adjusted PB Ratio Chart

Vascular Biogenics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vascular Biogenics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.13 0.18

STU:0VB vs MBIO, GNPX, LEXX: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Vascular Biogenics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vascular Biogenics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vascular Biogenics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vascular Biogenics's Cyclically Adjusted PB Ratio falls into.



Vascular Biogenics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Vascular Biogenics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 is calculated as:

For example, Vascular Biogenics's adjusted Book Value per Share data for the three months ended in Jun. 2023 was:

Adj_Book=Book Value per Share/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=0.226/305.1090*305.1090
=0.226

Current CPI (Jun. 2023) = 305.1090.

Vascular Biogenics Quarterly Data

Book Value per Share CPI Adj_Book
201309 0.000 234.149 0.000
201312 -1.429 233.049 -1.871
201403 0.000 236.293 0.000
201406 0.000 238.343 0.000
201409 0.127 238.031 0.163
201412 1.431 234.812 1.859
201503 1.503 236.119 1.942
201506 1.324 238.638 1.693
201509 1.069 237.945 1.371
201512 1.430 236.525 1.845
201603 1.219 238.132 1.562
201606 1.960 241.018 2.481
201609 1.544 241.428 1.951
201612 1.494 241.432 1.888
201703 1.325 243.801 1.658
201706 1.161 244.955 1.446
201709 0.926 246.819 1.145
201712 1.581 246.524 1.957
201803 1.365 249.554 1.669
201806 1.458 251.989 1.765
201809 1.353 252.439 1.635
201812 1.300 251.233 1.579
201903 1.223 254.202 1.468
201906 1.122 256.143 1.336
201909 1.041 256.759 1.237
201912 0.904 256.974 1.073
202003 0.788 258.115 0.931
202006 0.885 257.797 1.047
202009 0.659 260.280 0.773
202012 0.529 260.474 0.620
202103 0.600 264.877 0.691
202106 0.681 271.696 0.765
202109 0.615 274.310 0.684
202112 0.617 278.802 0.675
202203 0.502 287.504 0.533
202206 0.420 296.311 0.432
202209 0.329 296.808 0.338
202212 0.272 296.797 0.280
202303 0.239 301.836 0.242
202306 0.226 305.109 0.226

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vascular Biogenics Business Description

Address 8 HaSatat Street, Modi’in, ISR, 7178106
Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.